Panel Discussion on Equity, Diversity & Inclusion (ED&I): Expediting Liquid Biopsy Development & Validation for Early Screening to Advance Equity in Personalized Treatment

Time: 9:30 am
day: Day One


  • What are the benefits of capturing a diverse and inclusive genetic and molecular characteristic for advancing equity in early screening?
  • When examining research on biomarkers and clinical trials, do you believe there is a significant lack of inclusion in the design and execution of studies, and if so, what measures should be taken to address this deficiency?
  • Do patients of all demographics have equal access to clinical trials and personalized treatment? What are some of the operational barriers that impede patient access to clinical trials?
  • What should the ultimate impact be when it comes to approving drugs applicable to everyone, and what is the estimated timeline for achieving this level of inclusivity in pharmaceutical research and development?
  • What strategies can be implemented to address disparities in early cancer screening or inclusion in clinical research?
  • What steps are being taken to validate liquid biopsy assays across diverse patient populations, considering variations in genetic and molecular profiles, to tailor inclusive personalized treatment strategies?